BASi to Participate in H.C. Wainright Investment Conference
09 September 2020 - 10:33PM
Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi”, the
“Company”, “We” or “Our”), doing business as Inotiv, a
leading provider of nonclinical and analytical contract research
services, today announced that it will participate in the H.C.
Wainright 22nd Annual Global Investment Conference. The Company
will present on Wednesday, September 16th, at 2:30 p.m. EDT.
A live webcast of the presentation will be
available through a link that will be posted on the Investors
section of the Company’s website at ir.inotivco.com and will be
available for approximately 90 days.
About Bioanalytical Systems, Inc., operating as
Inotiv
BASi, operating as Inotiv, is a pharmaceutical
development company providing contract research services and
monitoring instruments to emerging pharmaceutical companies and the
world's leading drug development companies and medical research
organizations. The Company focuses on developing innovative
services supporting its clients’ discovery and development
objectives for improved decision-making and accelerated goal
attainment. BASi’s products focus on increasing efficiency,
improving data, and reducing the cost of taking new drugs to
market. Visit inotivco.com for more information about BASi,
operating as Inotiv.
This press release contains “forward looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Statements that are not historical facts are
forward-looking statements. Forward-looking statements are based on
current beliefs and assumptions that are subject to risks and
uncertainties. Forward-looking statements speak only as of the date
they are made, and the Company undertakes no obligation to update
any of them publicly in light of new information or future events.
Actual results could differ materially from those contained in any
forward-looking statement as a result of various factors. More
information, including potential risk factors, that could affect
the Company’s business and financial results are included in the
Company’s filings with the U.S. Securities and Exchange Commission,
including, but not limited to, the Company’s Forms 10-K, 10-Q and
8-K.
FOR MORE INFORMATION: |
Company Contact: |
|
Beth A. Taylor |
|
Chief Financial Officer |
|
Phone: 765.497.8381 |
|
btaylor@inotivco.com |
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Apr 2023 to Apr 2024
Real-Time news about Bioanalytical Systems Inc (NASDAQ): 0 recent articles
More News Articles